Cloning and expression of ADAM-related metalloproteases in equine laminitis

Veterinary Immunology and Immunopathology

Volumn 129, Issue 3-4, 2009, Pages 231-241

  Coyne, Michael J ^a   Cousin, Hélène ^a   Loftus, John P ^a   Johnson, Philip J ^b   Belknap, James K ^c   Gradil, Carlos M ^a   Black, Samuel J ^a   Alfandari, Dominique ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

ADAM; ADAMTS 4; Laminitis; Matrix metalloprotease; TIMP 1

Indexed keywords

ADAM PROTEIN; DISINTEGRIN; GELATINASE B; METALLOPROTEINASE; PROTEIN ADAM 10; PROTEIN ADAMTS 1; PROTEIN ADAMTS 4; PROTEIN ADAMTS 5; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HOOF AND CLAW; HORSE; HORSE DISEASE; LAMINITIS; MOLECULAR CLONING; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SOFT TISSUE;

ADAM PROTEINS; ANIMALS; BASE SEQUENCE; CLONING, MOLECULAR; FOOT DISEASES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HOOF AND CLAW; HORSE DISEASES; HORSES; INFLAMMATION; MOLECULAR SEQUENCE DATA;

ANIMALIA; EQUIDAE; JUGLANS NIGRA;

EID: 64749098676     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2008.11.022     Document Type: Article

References (76)

1. Alfandari D., Cousin H., Gaultier A., Smith K., White J.M., Darribere T., and DeSimone D.W. Xenopus ADAM 13 is a metalloprotease required for cranial neural crest-cell migration. Curr. Biol. 11 (2001) 918-930
2. Alfandari D., Whittaker C.A., DeSimone D.W., and Darribere T. Integrin alpha v subunit is expressed on mesodermal cell surfaces during amphibian gastrulation. Dev. Biol. 170 (1995) 249-261
3. Amour A., Knight C.G., Webster A., Slocombe P.M., Stephens P.E., Knauper V., Docherty A.J., and Murphy G. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett. 473 (2000) 275-279
4. Amour A., Slocombe P.M., Webster A., Butler M., Knight C.G., Smith B.J., Stephens P.E., Shelley C., Hutton M., Knauper V., Docherty A.J., and Murphy G. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 435 (1998) 39-44
5. Belknap J.K., Giguere S., Pettigrew A., Cochran A.M., Van Eps A.W., and Pollitt C.C. Lamellar pro-inflammatory cytokine expression patterns in laminitis at the developmental stage and at the onset of lameness: innate vs. adaptive immune response. Equine Vet. J. 39 (2007) 42-47
6. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., Castner B.J., Stocking K.L., Reddy P., Srinivasan S., Nelson N., Boiani N., Schooley K.A., Gerhart M., Davis R., Fitzner J.N., Johnson R.S., Paxton R.J., March C.J., and Cerretti D.P. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385 (1997) 729-733
7. Black S.J., Lunn D.P., Yin C., Hwang M., Lenz S.D., and Belknap J.K. Leukocyte emigration in the early stages of laminitis. Vet. Immunol. Immunopathol. 109 (2006) 161-166
8. Blikslager A.T., Yin C., Cochran A.M., Wooten J.G., Pettigrew A., and Belknap J.K. Cyclooxygenase expression in the early stages of equine laminitis: a cytologic study. J. Vet. Intern. Med. 20 (2006) 1191-1196
9. Blobel C.P. ADAMs: key components in EGFR signalling and development. Nat. Rev. Mol. Cell Biol. 6 (2005) 32-43
10. Chakrabarti S., and Patel K.D. Regulation of matrix metalloproteinase-9 release from IL-8-stimulated human neutrophils. J. Leukoc. Biol. 78 (2005) 279-288
11. Clegg P.D., Jones M.D., and Carter S.D. The effect of drugs commonly used in the treatment of equine articular disorders on the activity of equine matrix metalloproteinase-2 and 9. J. Vet. Pharmacol. Ther. 21 (1998) 406-413
12. Cousin H., Gaultier A., Bleux C., Darribere T., and Alfandari D. PACSIN2 is a regulator of the metalloprotease/disintegrin ADAM13. Dev. Biol. 227 (2000) 197-210
13. Cross N.A., Chandrasekharan S., Jokonya N., Fowles A., Hamdy F.C., Buttle D.J., and Eaton C.L. The expression and regulation of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbeta1 in prostate cells: relevance to the accumulation of versican. Prostate 63 (2005) 269-275
14. Eaton S.A., Allen D., Eades S.C., and Schneider D.A. Digital Starling forces and hemodynamics during early laminitis induced by an aqueous extract of black walnut (Juglans nigra) in horses. Am. J. Vet. Res. 56 (1995) 1338-1344
15. Fontaine G.L., Belknap J.K., Allen D., Moore J.N., and Kroll D.L. Expression of interleukin-1beta in the digital laminae of horses in the prodromal stage of experimentally induced laminitis. Am. J. Vet. Res. 62 (2001) 714-720
16. French K.R., and Pollitt C.C. Equine laminitis: loss of hemidesmosomes in hoof secondary epidermal lamellae correlates to dose in an oligofructose induction model: an ultrastructural study. Equine Vet. J. 36 (2004) 230-235
17. Galey F.D., Beasley V.R., Schaeffer D., and Davis L.E. Effect of an aqueous extract of black walnut (Juglans nigra) on isolated equine digital vessels. Am. J. Vet. Res. 51 (1990) 83-88
18. Galey F.D., Whiteley H.E., Goetz T.E., Kuenstler A.R., Davis C.A., and Beasley V.R. Black walnut (Juglans nigra) toxicosis: a model for equine laminitis. J. Comp. Pathol. 104 (1991) 313-326
19. Garner H.E., Coffman J.R., Hahn A.W., Hutcheson D.P., and Tumbleson M.E. Equine laminitis of alimentary origin: an experimental model. Am. J. Vet. Res. 36 (1975) 441-444
20. Garton K.J., Gough P.J., Blobel C.P., Murphy G., Greaves D.R., Dempsey P.J., and Raines E.W. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J. Biol. Chem. 276 (2001) 37993-38001
21. Gomez D.E., De Lorenzo M.S., Alonso D.F., and Andrade Z.A. Expression of metalloproteinases (MMP-1, MMP-2, and MMP-9) and their inhibitors (TIMP-1 and TIMP-2) in schistosomal portal fibrosis. Am. J. Trop. Med. Hyg. 61 (1999) 9-13
22. Grosenbaugh D.A., Morgan S.J., and Hood D.M. The digital pathologies of chronic laminitis. Vet. Clin. North Am. Equine Pract. 15 (1999) 419-436
23. Han Y.P. Matrix metalloproteinases, the pros and cons, in liver fibrosis. J. Gastroenterol. Hepatol. 21 Suppl. 3 (2006) S88-S91
24. Hashimoto G., Aoki T., Nakamura H., Tanzawa K., and Okada Y. Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4). FEBS Lett. 494 (2001) 192-195
25. Hashimoto G., Shimoda M., and Okada Y. ADAMTS4 (aggrecanase-1) interaction with the C-terminal domain of fibronectin inhibits proteolysis of aggrecan. J. Biol. Chem. 279 (2004) 32483-32491
26. Homandberg G.A., Meyers R., and Xie D.L. Fibronectin fragments cause chondrolysis of bovine articular cartilage slices in culture. J. Biol. Chem. 267 (1992) 3597-3604
27. Hu J., Van den Steen P.E., Sang Q.X., and Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 6 (2007) 480-498
28. Hudson M.P., Armstrong P.W., Ruzyllo W., Brum J., Cusmano L., Krzeski P., Lyon R., Quinones M., Theroux P., Sydlowski D., Kim H.E., Garcia M.J., Jaber W.A., and Weaver W.D. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J. Am. Coll. Cardiol. 48 (2006) 15-20
29. Hurley D.J., Parks R.J., Reber A.J., Donovan D.C., Okinaga T., Vandenplas M.L., Peroni J.F., and Moore J.N. Dynamic changes in circulating leukocytes during the induction of equine laminitis with black walnut extract. Vet. Immunol. Immunopathol. 110 (2006) 195-206
30. Johnson P.J., Kreeger J.M., Keeler M., Ganjam V.K., and Messer N.T. Serum markers of lamellar basement membrane degradation and lamellar histopathological changes in horses affected with laminitis. Equine Vet. J. 32 (2000) 462-468
31. Johnson P.J., Tyagi S.C., Katwa L.C., Ganjam V.K., Moore L.A., Kreeger J.M., and Messer N.T. Activation of extracellular matrix metalloproteinases in equine laminitis. Vet. Rec. 142 (1998) 392-396
32. Kahari V.M., and Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann. Med. 31 (1999) 34-45
33. Kashiwagi M., Tortorella M., Nagase H., and Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J. Biol. Chem. 276 (2001) 12501-12504
34. Kim T., Oh J., Woo J.M., Choi E., Im S.H., Yoo Y.J., Kim D.H., Nishimura H., and Cho C. Expression and relationship of male reproductive ADAMs in mouse. Biol. Reprod. 74 (2006) 744-750
35. Kyaw-Tanner M., and Pollitt C.C. Equine laminitis: increased transcription of matrix metalloproteinase-2 (MMP-2) occurs during the developmental phase. Equine Vet. J. 36 (2004) 221-225
36. Little C.B., Hughes C.E., Curtis C.L., Janusz M.J., Bohne R., Wang-Weigand S., Taiwo Y.O., Mitchell P.G., Otterness I.G., Flannery C.R., and Caterson B. Matrix metalloproteinases are involved in C-terminal and interglobular domain processing of cartilage aggrecan in late stage cartilage degradation. Matrix Biol. 21 (2002) 271-288
37. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25 (2001) 402-408
38. Loftus J.P., Belknap J.K., and Black S.J. Matrix metalloproteinase-9 in laminae of black walnut extract treated horses correlates with neutrophil abundance. Vet. Immunol. Immunopathol. 113 (2006) 267-276
39. Loftus J.P., Belknap J.K., Stankiewicz K.M., and Black S.J. Lamellar xanthine oxidase, superoxide dismutase and catalase activities in the prodromal stage of black-walnut induced equine laminitis. Equine Vet. J. 39 (2007) 48-53
40. Loftus J.P., Black S.J., Pettigrew A., Abrahamsen E.J., and Belknap J.K. Early lamellar events involving endothelial activation in horses with black walnut-induced laminitis. Am. J. Vet. Res. 68 (2007) 1205-1211
41. Loftus J., Johnson P., Belknap J.K., Pettigrew A., and Black S.J. Leukocyte-derived and endogenous matrix metalloproteinases in lamellae of horses with naturally acquired and experimentally induced laminitis. Vet. Immunol. Immunopathol. 129 (2009) 216-220
42. Ludwig A., and Weber C. Transmembrane chemokines: versatile 'special agents' in vascular inflammation. Thromb. Haemost. 97 (2007) 694-703
43. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front. Biosci. 11 (2006) 1696-1701
44. Malfait A.M., Liu R.Q., Ijiri K., Komiya S., and Tortorella M.D. Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J. Biol. Chem. 277 (2002) 22201-22208
45. Monaco S., Sparano V., Gioia M., Sbardella D., Di Pierro D., Marini S., and Coletta M. Enzymatic processing of collagen IV by MMP-2 (gelatinase A) affects neutrophil migration and it is modulated by extracatalytic domains. Protein Sci. 15 (2006) 2805-2815
46. Moss M.L., and Lambert M.H. Shedding of membrane proteins by ADAM family proteases. Essays Biochem. 38 (2002) 141-153
47. Mungall B.A., and Pollitt C.C. Zymographic analysis of equine laminitis. Histochem. Cell Biol. 112 (1999) 467-472
48. Nagase H., and Kashiwagi M. Aggrecanases and cartilage matrix degradation. Arthritis Res. Ther. 5 (2003) 94-103
49. Nagase H., Visse R., and Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69 (2006) 562-573
50. Noe M.C., Natarajan V., Snow S.L., Mitchell P.G., Lopresti-Morrow L., Reeves L.M., Yocum S.A., Carty T.J., Barberia J.A., Sweeney F.J., Liras J.L., Vaughn M., Hardink J.R., Hawkins J.M., and Tokar C. Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13. Bioorg. Med. Chem. Lett. 15 (2005) 2808-2811
51. Noe M.C., Natarajan V., Snow S.L., Wolf-Gouveia L.A., Mitchell P.G., Lopresti-Morrow L., Reeves L.M., Yocum S.A., Otterness I., Bliven M.A., Carty T.J., Barberia J.T., Sweeney F.J., Liras J.L., and Vaughn M. Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13. Bioorg. Med. Chem. Lett. 15 (2005) 3385-3388
52. Ortega N., Behonick D., Stickens D., and Werb Z. How proteases regulate bone morphogenesis. Ann. N. Y. Acad. Sci. 995 (2003) 109-116
53. Planting A., van der Gaast A., Schoffski P., Bartkowski M., Verheij C., Noe D., Ferrante K., and Verweij J. A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 55 (2005) 136-142
54. Pollitt C.C. Basement membrane pathology: a feature of acute equine laminitis. Equine Vet. J. 28 (1996) 38-46
55. Pollitt C.C., and Daradka M. Equine laminitis basement membrane pathology: loss of type IV collagen, type VII collagen and laminin immunostaining. Equine Vet. J. Suppl. (1998) 139-144
56. Pollitt C.C., Pass M.A., and Pollitt S. Batimastat (BB-94) inhibits matrix metalloproteinases of equine laminitis. Equine Vet. J. Suppl. (1998) 119-124
57. Ravanti L., and Kahari V.M. Matrix metalloproteinases in wound repair (review). Int. J. Mol. Med. 6 (2000) 391-407
58. Rundhaug J.E. Matrix metalloproteinases and angiogenesis. J. Cell Mol. Med. 9 (2005) 267-285
59. Sahin U., Weskamp G., Kelly K., Zhou H.M., Higashiyama S., Peschon J., Hartmann D., Saftig P., and Blobel C.P. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J. Cell Biol. 164 (2004) 769-779
60. Schlondorff J., and Blobel C.P. Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. J. Cell Sci. 112 Part 21 (1999) 3603-3617
61. Sloet van Oldruitenborgh-Oosterbaan M.M. Laminitis in the horse: a review. Vet. Q. 21 (1999) 121-127
62. Song R.H., Tortorella M.D., Malfait A.M., Alston J.T., Yang Z., Arner E.C., and Griggs D.W. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum. 56 (2007) 575-585
63. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J. Pathol. 200 (2003) 448-464
64. Stanton H., Ung L., and Fosang A.J. The 45 kDa collagen-binding fragment of fibronectin induces matrix metalloproteinase-13 synthesis by chondrocytes and aggrecan degradation by aggrecanases. Biochem. J. 364 (2002) 181-190
65. Sugimoto K., Takahashi M., Yamamoto Y., Shimada K., and Tanzawa K. Identification of aggrecanase activity in medium of cartilage culture. J. Biochem. (Tokyo) 126 (1999) 449-455
66. Tanaka S., Hamanishi C., Kikuchi H., and Fukuda K. Factors related to degradation of articular cartilage in osteoarthritis: a review. Semin. Arthritis Rheum. 27 (1998) 392-399
67. Thomsen M.E., Davis E.G., and Rush B.R. Black walnut induced laminitis. Vet. Hum. Toxicol. 42 (2000) 8-11
68. Tortorella M., Pratta M., Liu R.Q., Abbaszade I., Ross H., Burn T., and Arner E. The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage. J. Biol. Chem. 275 (2000) 25791-25797
69. Tortorella M.D., Malfait A.M., Deccico C., and Arner E. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage 9 (2001) 539-552
70. Uhlinger C. Black walnut toxicosis in ten horses. J. Am. Vet. Med. Assoc. 195 (1989) 343-344
71. Waguespack R.W., Cochran A., and Belknap J.K. Expression of the cyclooxygenase isoforms in the prodromal stage of black walnut-induced laminitis in horses. Am. J. Vet. Res. 65 (2004) 1724-1729
72. Waguespack R.W., Kemppainen R.J., Cochran A., Lin H.C., and Belknap J.K. Increased expression of MAIL, a cytokine-associated nuclear protein, in the prodromal stage of black walnut-induced laminitis. Equine Vet. J. 36 (2004) 285-291
73. Werb Z., and Chin J.R. Extracellular matrix remodeling during morphogenesis. Ann. N. Y. Acad. Sci. 857 (1998) 110-118
74. Wojtowicz-Praga S. Clinical potential of matrix metalloprotease inhibitors. Drugs R D 1 (1999) 117-129
75. Wolfsberg T.G., Straight P.D., Gerena R.L., Huovila A.P., Primakoff P., Myles D.G., and White J.M. ADAM, a widely distributed and developmentally regulated gene family encoding membrane proteins with a disintegrin and metalloprotease domain. Dev. Biol. 169 (1995) 378-383
76. Xue M., Le N.T., and Jackson C.J. Targeting matrix metalloproteases to improve cutaneous wound healing. Expert Opin. Ther. Targets 10 (2006) 143-155